Derek Blevins1, Chamindi Seneviratne2, Xin-Qun Wang3, Bankole A Johnson4, Nassima Ait-Daoud5. 1. Department of Psychiatry, Columbia University Irving Medical Center/New York State Psychiatric Institute, New York, NY, United States. Electronic address: derek.blevins@nyspi.columbia.edu. 2. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, United States. 3. Department of Public Health Sciences, University of Virginia, Charlottesville, VA, United States. 4. Department of Psychiatry & Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, United States (Former affiliation). 5. Department of Psychiatry & Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, United States.
Abstract
BACKGROUND: Cocaine use disorder (CUD) has significant consequences and there remain no FDA-approved pharmacotherapies. Ondansetron is an indirect dopaminergic modulator that has shown efficacy in alcohol use disorder, particularly in phenotypic and genotypic subgroups, and was found to be efficacious in a pilot dose-finding trial for CUD. METHODS: One-hundred eight (108) adults with CUD were randomized to ondansetron 4 mg twice daily or placebo for 9 weeks and assessed up to thrice weekly to evaluate self-reported cocaine use and urine benzoylecgonine. Participants received cognitive-behavioral therapy and brief behavioral compliance enhancement therapy. Consenting participants (N = 79) provided blood samples for exploratory pharmacogenetic analyses. RESULTS: Participants in both arms reduced cocaine use over time, but there was no statistically significant difference on percentage of cocaine-free days (PCFD; p = 0.972) or percentage of cocaine-free urine samples (PCFU; p = 0.909). Participants with early-onset CUD had greater improvement regardless of study arm (p = 0.002). Post hoc pharmacogenetic analyses demonstrated an interaction effect between treatment and rs1176713 SNP on PCFU in the total sample (p = 0.040) and African ancestry subset (p = 0.03). Constipation, fatigue, and somnolence were more common among ondansetron-treated participants (Fisher exact p < 0.05). Those who developed constipation were mostly rs1176713:GG carriers (Fisher exact p = 0.029). CONCLUSIONS: Ondansetron did not demonstrate efficacy in the treatment of CUD. However, these preliminary results suggest a genotype-based variance in response to ondansetron in African ancestry individuals with CUD. Further studies are needed to validate findings for developing a personalized genomic approach for CUD treatment in racially and ethnically diverse populations.
BACKGROUND: Cocaine use disorder (CUD) has significant consequences and there remain no FDA-approved pharmacotherapies. Ondansetron is an indirect dopaminergic modulator that has shown efficacy in alcohol use disorder, particularly in phenotypic and genotypic subgroups, and was found to be efficacious in a pilot dose-finding trial for CUD. METHODS: One-hundred eight (108) adults with CUD were randomized to ondansetron 4 mg twice daily or placebo for 9 weeks and assessed up to thrice weekly to evaluate self-reported cocaine use and urine benzoylecgonine. Participants received cognitive-behavioral therapy and brief behavioral compliance enhancement therapy. Consenting participants (N = 79) provided blood samples for exploratory pharmacogenetic analyses. RESULTS: Participants in both arms reduced cocaine use over time, but there was no statistically significant difference on percentage of cocaine-free days (PCFD; p = 0.972) or percentage of cocaine-free urine samples (PCFU; p = 0.909). Participants with early-onset CUD had greater improvement regardless of study arm (p = 0.002). Post hoc pharmacogenetic analyses demonstrated an interaction effect between treatment and rs1176713 SNP on PCFU in the total sample (p = 0.040) and African ancestry subset (p = 0.03). Constipation, fatigue, and somnolence were more common among ondansetron-treated participants (Fisher exact p < 0.05). Those who developed constipation were mostly rs1176713:GG carriers (Fisher exact p = 0.029). CONCLUSIONS: Ondansetron did not demonstrate efficacy in the treatment of CUD. However, these preliminary results suggest a genotype-based variance in response to ondansetron in African ancestry individuals with CUD. Further studies are needed to validate findings for developing a personalized genomic approach for CUD treatment in racially and ethnically diverse populations.
Authors: J Grabowski; H Rhoades; J Schmitz; A Stotts; L A Daruzska; D Creson; F G Moeller Journal: J Clin Psychopharmacol Date: 2001-10 Impact factor: 3.153
Authors: Bruna Mayara Lopes; Priscila Dib Gonçalves; Mariella Ometto; Bernardo Dos Santos; Mikael Cavallet; Tiffany Moukbel Chaim-Avancini; Mauricio Henriques Serpa; Sergio Nicastri; André Malbergier; Geraldo F Busatto; Arthur Guerra de Andrade; Paulo Jannuzzi Cunha Journal: Addict Behav Date: 2017-04-29 Impact factor: 3.913
Authors: Diana Martinez; Kenneth M Carpenter; Fei Liu; Mark Slifstein; Allegra Broft; Alessandra Calvo Friedman; Dileep Kumar; Ronald Van Heertum; Herbert D Kleber; Edward Nunes Journal: Am J Psychiatry Date: 2011-03-15 Impact factor: 18.112